

The use of readily available laboratory tests for the identification of the emerging yeast *Candida auris* in Mexico

Diego Hernando Caceres (✉ diegocaceres84@gmail.com)

Radboud University Medical Center <https://orcid.org/0000-0001-8749-9809>

González-Durán Elizabeth

INDRE

Ríos-Rosas Claudia

INDRE

Téllez-Saucedo M Dolores

INDRE

Ramírez-González J Ernesto

INDRE

Ramírez-Barríos J Gabriela

INDRES

Martínez-Montiel Nancy

BUAP

Martínez-Contreras Rebeca

BUAP

García-Ruíz Pablo

INDRE

Salazar-Sánchez M Isabel

ENCB

Hernández-Rivas Lucia

INDRE

López-Martínez Irma

INDRE

Research Article

Keywords: *Candida auris*, laboratory identification, antifungal resistance

Posted Date: April 8th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1516575/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Identification of the emerging multidrug resistant yeast *Candida auris* is challenging. Here we described the role of the Mexico national reference laboratory Instituto de Diagnóstico y Referencia Epidemiológicos Dr. Manuel Martínez Báez (InDRE) and the Mexican national laboratory network in the identification of *C. auris*. Reference identification was performed based on phenotypic and molecular laboratory methods, including growth in special media, evaluation of isolate micromorphology, and species-specific PCR and pan-fungal PCR and sequencing. *C. auris* isolates were able to grow on modified Sabouraud agar with 10% NaCl incubated at 40°C. With one exception, isolates of *C. auris* were spherical to ovoid yeast-like cells and blastoconidia, with no hyphae or pseudohyphae on cornmeal agar. *C. auris* isolates were resistant to fluconazole. Species-specific and pan-fungal PCR confirmed isolates as *C. auris*. Sequence analysis revealed the presence of two different *C. auris* clades in Mexico, clade I (South Asia) and clade IV (South America).

Introduction

Candida auris is an emerging multidrug resistance yeast able to cause invasive fungal infections and hospital outbreaks. This species of *Candida* differs from other species in that it more readily spreads from patient to patient in healthcare settings through contact with contaminated environmental surfaces or equipment (1, 2). In addition, the laboratory identification of *C. auris* using commercially available methods for yeast identification is challenging because most of the systems used for yeast identification, such as Phoenix BD, API 20 and MicroScan, misidentify *C. auris* as other *Candida* species (3), mainly species of the *C. haemulonii* species complex (2, 4), but also as *C. famata*, *C. guilliermondii*, *C. lusitaniae*, *C. glabrata*, *C. parapsilosis* and *C. catenulata* (5). Currently, the most reliable methods for identification of *C. auris* include the VITEK® 2 with the most current software update, MALDI-TOF, molecular methods using specific PCR assays (4, 6, 7), or by the amplification and sequencing of the ITS1-ITS2 or the D1/D2 region of the ribosomal cistron (7–10).

In Mexico, *C. auris* was reported for the first time in May 2020 in a woman with severe endometriosis (11). Three months later the same hospital reported a large outbreak of *C. auris* associated with high mortality in patients with severe COVID-19 (12). The impact of the current COVID-19 pandemic resulted in overcrowded hospitals, with larger numbers of critically ill patients at increased risk of invasive candidiasis. These overcrowded conditions set the stage for an increase in hospital-associated infections, including those caused by *C. auris* (13).

Here, we describe the role of the Mexico national reference laboratory, Instituto de Diagnóstico y Referencia Epidemiológicos Dr. Manuel Martínez Báez (InDRE), and the Mexican national laboratory network in the detection of emerging problems, and the identification of the emerging yeast *C. auris*. This report presents a summary of the microbiological characteristics, focused on the phenotypic and molecular characteristics of Mexican isolates proven to be *C. auris*.

Material And Methods

Phenotypic identification. Suspected isolates were grown on Sabouraud dextrose agar (SDA) incubated at 30°C for 120 hours. In parallel, isolates were grown on a selective modified Sabouraud agar (1), supplemented with 10% NaCl (Sab-10% NaCl) and dulcitol instead of dextrose as carbon source. Isolates on this media were incubated at 40°C for 72 hours. In addition, morphological characteristics of isolates were evaluated, including growth on Cornmeal agar.

Isolates were also tested using the VITEK® 2 system. Identification was performed using VITEK® 2 YST cards and results were analyzed using the software version 8.01 (bioMérieux, Marcy, L'Etoile, France). Additionally, assimilation of the following carbohydrates was evaluated: glucose, galactose, cellobiose, raffinose, melezitose, rhamnose, trehalose, dulcitol and xylose.

Molecular identification. Genomic DNA (gDNA) extraction was performed using the FastDNA™ kit (MP Biomedicals, USA) and the FastPrep® equipment as suggested by the manufacturer. Lysed material was further purified using the QIAamp® DNA Mini Kit (QIAGEN, Hilden, Germany).

Two PCR amplifications were used for molecular identification. The first was a pan-fungal PCR targeting the internal transcribed spacers (ITS1-ITS2) of the ribosomal cistron using primers ITS1F (5'-TCCGTAGGTGAACCTGCGG-3') and ITS4R (5'-TCCTCCGCTTATTGATATGC-3'). The second amplification was a species-specific PCR for *C. auris* using primers ITS1F and CaurisR (5'-CCACCGCGAAGATTGGTG-3'). The PCR conditions have been previously described (14), and PCR products were sequenced by the Sanger method (15). Sequence analysis was done using the nBLAST tool at the NCBI database (<http://www.ncbi.nlm.nih.gov/blast>). A phylogenetic tree of our data and the ITS regions of 20 non-redundant sequences extracted from the GenBank database were constructed using MEGA7.0 software and Jukes-Cantor nucleotide substitution model with 1000 bootstraps (16).

Fluconazole susceptibility testing

fluconazole (FLU) susceptibility testing was performed using the agar dilution method, as previously described (17). Minimum inhibitory concentration (MIC) was assessed in concentrations ranging from 2 to 256 µg/ml. After 48h incubation, the MIC was determined as the lowest concentration that inhibits yeast growth (18). For susceptibility testing, *Candida parapsilosis* (ATCC 22019) was used as a susceptible strain, and *Candida krusei* (PAHO-ARG13) as a resistant strain (CLSI-M60). *Candida auris* MIC values for were interpreted using the tentative cutoff values proposed by the CDC (MIC ≥ 32 µg/mL) (19).

Results

Six isolates suspected to be *C. auris* were submitted to InDRE for species identification. One blood and two urine isolates came from a private hospital at the state of Nuevo León (labeled MYC-28, MYC-29, and MYC-30). The other three isolates were referred from public hospitals: a sputum isolate from Tabasco

state (MYC-43), a blood isolate from Querétaro state (MYC-121), and a urine isolate from Morelos state (MYC-221). Before shipment, MYC-28, MYC-29 and MYC-30 were identified as *C. auris* using MALDI-TOF MS Bruker, and MYC-43 as *C. auris*, MYC-121 as *C. krusei*, and MYC-221 as *C. parapsilosis* using the VITEK® 2 system, v8.01 software. Four isolates were from men and two from women, with a median age of 59 years (range: 54–78 years). All patients were diagnosed with COVID-19 and were hospitalized in the intensive care unit (ICU). Median ICU stay was 35 days (range: 23–71 days). Five of the six patients died.

Using phenotypic methods, we found that isolates originally identified as *C. auris* (MYC-28, MYC-29, MYC-30 and MYC-43) grew on SDA at 37°C and Sab-10% NaCl at 40°C, Microscopic examination revealed spherical and ovoid yeast-like cells and blastoconidia, but chytrid-like cells and hyphae or pseudohyphae were not observed on cornmeal agar for isolates MYC-28, MYC-29, MYC-30 (Fig. 1A). Isolate MYC-43 displayed chytrid-like cells and hyphae or pseudohyphae on cornmeal agar (Fig. 1B). Isolates originally identified as *C. parapsilosis* and *C. krusei* did not grow in Sab-10% NaCl at 40°C and produced pseudohyphae and chytrid-like cells on cornmeal agar (Fig. 1C and 1D).

Assimilation of carbohydrates testing shows that isolates originally identified as *C. auris* (MYC-28, MYC-29, MYC-30 and MYC-43) assimilated five of the nine carbohydrates tested: glucose, raffinose, melezitose, trehalose and dulcitol. Final species identification was performed using the species-specific *C. auris* PCR. An approximately 279 bp band was amplified for MYC-28, MYC-29, MYC-30 and MYC-43 isolates while no amplification was observed for isolates MYC-121 and MYC-221 (Fig. 2). Using pan-fungal PCR sequencing, *C. auris* isolates had 99–100% identity with other *C. auris* sequences within GenBank. Phylogenetic analysis of the sequence of ITS1-ITS2 regions showed that Mexican *C. auris* isolates were clustered with the *C. auris* South American clade (clade IV) for isolates MYC-28, MYC-29 and MYC-30, and isolate MYC-43 grouped with *C. auris* South Asian clade (clade I) (10) (Fig. 3). Sequences were deposited at the GenBank database under accession numbers MW358012 (MYC-28), MW358013 (MYC-29), MW358014 (MYC-30), MZ648436 (MYC-43), MZ020643 (MYC-121) and MZ020644 (MYC-221).

Fluconazole susceptibility testing of the four *C. auris* isolates showed high MIC values. Isolates MYC-28, MYC-43, MYC-29 and MYC-30 had MICs of 128 µg/mL, based on proposed breakpoints (MIC ≥ 32) these isolates were considered resistant to fluconazole (19).

Discussion

The national laboratory surveillance confirmed four cases of *C. auris* in Mexico belonging to two different clades, all cases were identified in patients in the ICU with severe COVID-19. With the identification of *C. auris* in several Mexican states and the increase in the number of patients hospitalized in ICUs as a result of the COVID-19 pandemic, the mycology reference service of the InDRE implemented national laboratory surveillance for *C. auris*. Several challenges had to be addressed during the implementation of this surveillance, especially the limited availability of reference methods, such as MALDI-TOF, for the confirmation of *C. auris*.

In combination with several other low-cost tests, we were able to successfully use species-specific PCR for definitive identification of *C. auris* in a resource-limited setting, obtaining reliable and comparable results as those obtained with the reference methods. *Candida auris*-specific PCR tests have been used for the identification of colonized patients by the direct detection of *C. auris* DNA on skin swabs (20). This type of non-culture based methodology has shown relevant utility in the early detection and control of *C. auris* outbreaks (21). Here, we have used this test to definitively identify isolates of *C. auris* using simple PCR and gel electrophoresis rather than real time PCR. We have shown that this test could be employed in combination with other simple tests when MALDI-TOF and DNA sequencing are not available.

Without specialized *Candida* chromogenic media, the use of basic mycology methods, such as the evaluation of growth under different culture conditions, such as high salt and high temperature, were key to identifying potential isolates of *C. auris*. On cornmeal agar, *C. auris* generally has homogeneous size and shaped blastoconidia and no hyphae and pseudohyphae. However, one of the four isolates did present pseudohyphae, showing that is not a definitive characteristic of *C. auris*.

The evaluation of the profile of carbohydrates assimilation it is not widely used for identification of *Candida* spp, mainly because it is a complex and laborious laboratory method. We confirmed that dulcitol assimilation is key to identify *C. auris* to other closely related species of *Candida* (1–3). Despite the close genetic relationship between *C. auris* and the *C. haemulonii* complex, the biochemical assimilation profile between them is distinct, so that a four carbohydrate assimilation combination (galactose, raffinose, rhamnose and dulcitol) is decisive for the differentiation of *C. auris* from the *C. haemulonii* species complex (2).

Using the VITEK® 2 system, we found that all four isolates were correctly identified as *C. auris*. As reported previously, VITEK® 2 system using the software version 8.01 is able to identify *C. auris*, especially isolates from the South American clade (clade IV) (22).

Here we observed all isolates were resistant to fluconazole, with high MIC values ($\geq 128 \mu\text{g/mL}$). This high resistance to fluconazole is similar to others reports around the world. Unfortunately, our information about antifungal susceptibility testing (AFST) had the limitation of not being a gold standard methodology, but it is important to highlight that the method used is a viable alternative in settings where access to AFST using broth microdilution or gradient diffusion is not available.

Phylogenetic analysis of sequences showed that the three Mexican *C. auris* isolates from the north of the country belonged to the South American clade, (clade IV). Surprisingly, the Mexican *C. auris* isolate from the south of the country clustered with the South Asian clade (Clade I), indicating that there have been multiple introductions of *C. auris* into Mexico and several clades are now circulating through the population.

With limited resources and limited access to reference methods for *Candida* species identification such as MALDI-TOF we were able to confirm the species identification of isolates suspected to be *C. auris*. Here we describe how conventional mycology laboratory methods, such as microscopy, growth on

differential media and growth at elevated temperatures were key aspects to tentative identification of *C. auris*. The use of a simple species-specific PCR test confirmed the tentative identification. These methods can all be easily implemented in laboratories in countries with limited resources, or with logistical difficulties in accessing reference methods for *Candida* identification.

Declarations

Acknowledgements: We would like to thank the State Laboratory Network of Public Health (LESP) and the Support Laboratory in Epidemiological Surveillance (LAVE-IMSS) to contribution for the epidemiological surveillance of *C. auris* and other species.

Compliance with Ethical Standards

Conflict of interest: The authors declare that they have no conflict of interest. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the Instituto de Diagnóstico y Referencia Epidemiológicos Dr. Manuel Martínez Báez (InDRE).

Ethical approval: This article does not contain any studies with human participants performed by any of the authors.

References

1. Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ et al (2017) Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast *Candida auris* on a Plastic Health Care Surface. *J Clin Microbiol* 55(10):2996–3005
2. Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM, Borman A et al (2018) *Candida auris*: a Review of the Literature. *Clin Microbiol Rev.* ; 31(1)
3. Caceres DH, Forsberg K, Welsh RM, Sexton DJ, Lockhart SR, Jackson BR et al (2019) *Candida auris*: A Review of Recommendations for Detection and Control in Healthcare Settings. *J Fungi (Basel).* ; 5(4)
4. Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A et al (2015) Multidrug-Resistant *Candida auris* Misidentified as *Candida haemulonii*: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method. *J Clin Microbiol* 53(6):1823–1830
5. Carvajal-Valencia SK, Lizarazo D, Duarte C, Escandon P (2020) Identificación de aislamientos de *Candida auris* recuperados a través de la vigilancia por laboratorio en Colombia: un reto para el diagnóstico. *Infectio* 24:224–228

6. Kordalewska M, Zhao Y, Lockhart SR, Chowdhary A, Berrio I, Perlin DS (2017) Rapid and Accurate Molecular Identification of the Emerging Multidrug-Resistant Pathogen *Candida auris*. *J Clin Microbiol* 55(8):2445–2452
7. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H (2009) *Candida auris* sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. *Microbiol Immunol* 53(1):41–44
8. Lockhart SR, Jackson BR, Vallabhaneni S, Ostrosky-Zeichner L, Pappas PG, Chiller T (2017) Thinking beyond the Common *Candida* Species: Need for Species-Level Identification of *Candida* Due to the Emergence of Multidrug-Resistant *Candida auris*. *J Clin Microbiol* 55(12):3324–3327
9. Lockhart SR, Berkow EL, Chow N, Welsh RM (2017) *Candida auris* for the clinical microbiology laboratory: Not your grandfather's *Candida* species. *Clin Microbiol Newsl* 39(13):99–103
10. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP et al (2017) Simultaneous Emergence of Multidrug-Resistant *Candida auris* on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. *Clin Infect Dis* 64(2):134–140
11. Ayala-Gaytán JJ, Montoya AM, Martínez-Resendez MF, Guajardo-Lara CE, de Salazar-Cavazos JT-RR (2021) First case of *Candida auris* isolated from the bloodstream of a Mexican patient with serious gastrointestinal complications from severe endometriosis. *Infection* 49(3):523–525
12. Villanueva-Lozano H, Treviño-Rangel RJ, González GM, Ramírez-Elizondo MT, Lara-Medrano R, Aleman-Bocanegra MC et al (2021) Outbreak of *Candida auris* infection in a COVID-19 hospital in Mexico. *Clin Microbiol Infect* 27(5):813–816
13. Chowdhary A, Sharma A (2020) The lurking scourge of multidrug resistant *Candida auris* in times of COVID-19 pandemic. *J Glob Antimicrob Resist* 22:175–176
14. Theill L, Dudiuk C, Morales-Lopez S, Berrio I, Rodriguez JY, Marin A et al (2018) Single-tube classical PCR for *Candida auris* and *Candida haemulonii* identification. *Rev Iberoam Micol* 35(2):110–112
15. Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci U S A* 74(12):5463–5467
16. Kumar S, Stecher G, Tamura K (2016) MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. *Mol Biol Evol* 33(7):1870–1874
17. Pérez CC, García PG, Parra LGB, Sánchez SP, Méndez JD (2019) *Candida Lusitaniae*. ISOLATION, IDENTIFICATION AND CLINICAL RELEVANCE.
18. CLSI (2017) [Available from: <https://clsi.org/>]
19. (CDC) CfDCaP. Recommendations for Identification of *Candida auris* (2018) [Available from: <https://www.cdc.gov/fungal/candida-auris/recommendations.html>]
20. Walchak RC, Buckwalter SP, Zinsmaster NM, Henn KM, Johnson KM, Koelsch JM et al (2020) *Candida auris* Direct Detection from Surveillance Swabs, Blood, and Urine Using a Laboratory-Developed PCR Method. *J Fungi (Basel)*. ; 6(4)

21. (CDC) CfDCaP. Recommendations for Infection Prevention and Control for *Candida auris* (2018)
[Available from: <https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html>]
22. Ambaraghassi G, Dufresne PJ, Dufresne SF, Vallieres E, Munoz JF, Cuomo CA et al (2019)
Identification of *Candida auris* using the updated 8.01 VITEK(R)2 yeast identification system: a multi-laboratory evaluation study. *J Clin Microbiol*.

Figures

Figure 1

Culture on cornmeal agar at 30°C, for 3 to 5 days. 40X. (A) *Candida auris*, clade IV, Nuevo León, Mexico. Yeasts alone and some with blastoconidia, the size and spherical shape is a constant characteristic that differentiates it from other species. (B) *Candida auris*, clade I, Tabasco, Mexico. Yeasts alone, with chlamydoconidia and hyphae or pseudohyphae. (C) *Candida parapsilosis*. Yeasts alone, with blastoconidia, pseudohyphae alone or branched. Incipient or immature chlamydoconidia. The cells adopt a characteristic irregular size and shape. (D) *Candida krusei*. Septate hyphae with spherical, ovoid and elongated lateral blastoconidia on the sides. Bilateral symmetry seems to be a differential characteristic in this species

Figure 2

See image above for figure legend

Figure 3

Phylogenetic tree of maximum likelihood III of the ITS1-ITS2 region of the partial region of the 18S gene, ITS1, 5.8S, ITS2 complete region and the partial sequence of the 28S gene of the rDNA, with the evolutionary model JC and 1000 bootstraps, MEGA 7.0v. Clades with sequences representing the 4 clades of *C. auris*. *C. auris* isolates from the state of Nuevo León (MYC-28, MYC-29 and MYC-30) matched with *C. auris* isolates corresponding to the South American clade (IV), and the isolate from Tabasco state (MYC-43) matched with *C. auris* isolates corresponding to the South Asian clade (I)